Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Medtronic plc    MDT   IE00BTN1Y115

MEDTRONIC PLC

(MDT)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Medtronic : Names Sean Salmon Executive VP, President of Diabetes Group

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/21/2019 | 07:24am EST

By Colin Kellaher

Medtronic PLC (MDT) on Monday said it named Sean Salmon executive vice president and president of its diabetes group.

The Dublin-based medical-technology company said Mr. Salmon succeeds Hooman Hakami, who is leaving Medtronic.

Mr. Salmon, who joined Medtronic in 2004, had been senior vice president and president of the coronary and structural heart business within the company's cardiac and vascular group. Medtronic said Mr. Salmon will serve on its executive committee.

Medtronic said Mr. Hakami, who had been executive vice president and president of the diabetes group since June 2014, will remain an adviser on an as-needed basis through February to assist with the transition.

The company said it still expects the diabetes group to post low-single-digit organic revenue growth in the current quarter. The group accounted for $592 million of the $7.5 billion of revenue Medtronic reported for the fiscal first quarter ended July 26.

Write to Colin Kellaher at colin.kellaher@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDTRONIC PLC
11/20LivaNova to shelve mitral heart valve device programme in restructuring
RE
11/19MEDTRONIC : Reaffirms Revenue Growth Guidance, Updates Segment Outlook
DJ
11/19US companies stuck with lawsuits and investigations
11/19MEDTRONIC : Raises Adjusted EPS Guidance, Beats 2Q Expectations
DJ
11/19MEDTRONIC : Fiscal 2Q Earnings Snapshot
AQ
11/19MEDTRONIC PLC : Results of Operations and Financial Condition (form 8-K)
AQ
11/19Medtronic Reports Second Quarter Financial Results
GL
11/14Medtronic Highlights Leadership in Inclusion, Diversity, and Equity in 2019 I..
GL
11/14MEDTRONIC PLC : half-yearly earnings release
11/12MEDTRONIC : New Study Shows Promise in Treating More Patients with World's Small..
AQ
More news
Financials (USD)
Sales 2020 31 496 M
EBIT 2020 9 254 M
Net income 2020 5 852 M
Debt 2020 17 389 M
Yield 2020 1,90%
P/E ratio 2020 26,2x
P/E ratio 2021 24,3x
EV / Sales2020 5,31x
EV / Sales2021 4,95x
Capitalization 150 B
Chart MEDTRONIC PLC
Duration : Period :
Medtronic plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDTRONIC PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,50  $
Last Close Price 111,79  $
Spread / Highest target 19,9%
Spread / Average Target 8,69%
Spread / Lowest Target -1,60%
EPS Revisions
Managers
NameTitle
Omar S. Ishrak Chairman & Chief Executive Officer
Geoffrey Straub Martha President & Director
Mark Ploof Senior VP-Global Operations & Business Services
Karen L. Parkhill Chief Financial & Accounting Officer, Executive VP
Richard E. Kuntz Chief Scientific, Clinical & Regulatory Officer
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC22.90%149 841
BAXTER INTERNATIONAL INC.24.58%41 697
HOYA CORPORATION51.29%33 790
ZIMMER BIOMET HOLDINGS37.46%29 730
TERUMO CORPORATION-38.05%26 363
ALIGN TECHNOLOGY28.33%21 406